Stock 1312 KONTAFARMA CHINA HOLDINGS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Kontafarma China Holdings Limited Stock

Equities

1312

KYG8918D1088

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:09 2024-04-25 am EDT 		5-day change 1st Jan Change
0.032 HKD +14.29% Intraday chart for Kontafarma China Holdings Limited -5.88% -11.11%
Apr. 19 Kontafarma China Holdings Limited Announces Management Changes, Effect from 19 April 2024 CI
Mar. 28 Kontafarma China Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2021 961M 123M Sales 2022 894M 114M Capitalization 251M 32.12M
Net income 2021 -15M -1.92M Net income 2022 -41M -5.24M EV / Sales 2021 0.85 x
Net Debt 2021 545M 69.6M Net Debt 2022 448M 57.23M EV / Sales 2022 0.78 x
P/E ratio 2021
-18.2 x
P/E ratio 2022
-6.04 x
Employees 720
Yield 2021 *
-
Yield 2022
-
Free-Float 34.03%
More Fundamentals * Assessed data

Chart Kontafarma China Holdings Limited

Dynamic Chart

Latest news about Kontafarma China Holdings Limited

Kontafarma China Holdings Limited Announces Management Changes, Effect from 19 April 2024 CI
Kontafarma China Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Kontafarma China Warns of Up to HK$74 Million Loss in 2023 MT
Kontafarma China Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023 CI
Kontafarma China Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Kontafarma China to Swing to H1 Profit MT
Kontafarma China Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023 CI
Kontafarma China's Fitness Unit Renews Rent in Singapore Mall; Shares Up 3% MT
Kontafarma China Unit to Sell 66% Equity Interest of Shaanxi Unisplendour for 168.2 Million Yuan; Shares Slip 7% MT
Kontafarma China Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Kontafarma China Warns of Bigger Loss in 2022 MT
Kontafarma China Holdings Limited Provides Group Earnings Guidance for the Year Ended December 31, 2022 CI
Tongfang Kontafarma Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Tongfang Kontafarma Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022 CI
Tongfang Kontafarma Shareholders to Vote June 20 on $24 Million Sale of Majority Stake in SPF Biotechnology MT
More news

Press releases Kontafarma China Holdings Limited

Tongfang Kontafarma : DELAY IN DESPATCH OF CIRCULAR IN RELATION TO DISCLOSEABLE AND CONNECTED TRANSACTION PU
Tongfang Kontafarma : ANNUAL GENERAL MEETING FORM OF PROXY PU
Tongfang Kontafarma : PROPOSALS FOR RE-ELECTION OF DIRECTORS, GENERAL MANDATES TO ISSUE SECURITIES AND BUY BACK SHARES, AND NOTICE OF ANNUAL GENERAL MEETING PU
Tongfang Kontafarma : DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE CONSTRUCTION CONTRACTS PU
Tongfang Kontafarma : INSIDE INFORMATION ANNOUNCEMENT LEGAL PROCEEDINGS PU
More press releases

Quotes and Performance

1 day+14.29%
1 week-5.88%
1 month+3.23%
3 months+3.23%
Current year-11.11%
More quotes

Highs and lows

1 week
0.03
Extreme 0.028
0.04
1 month
0.03
Extreme 0.028
0.04
Current year
0.03
Extreme 0.028
0.04
1 year
0.03
Extreme 0.026
0.05
3 years
0.03
Extreme 0.026
0.09
5 years
0.03
Extreme 0.026
0.31
10 years
0.03
Extreme 0.026
2.03
More quotes

Managers and Directors - Kontafarma China Holdings Limited

Managers TitleAgeSince
Chao Wen Jiang CEO
 Chief Executive Officer 58 17-12-10
Man Wai Si Tou DFI
 Director of Finance/CFO 47 14-11-06
Jie Zhang COO
 Chief Operating Officer 41 20-09-02
Members of the board TitleAgeSince
Sze Chung Chan BRD
 Director/Board Member 54 11-12-19
Rui Bin Zhang BRD
 Director/Board Member 52 14-07-23
Yu Huang BRD
 Director/Board Member 55 14-03-14
More insiders

Quotes

Date Price Change Volume
24-04-25 0.032 +14.29% 6 000
24-04-24 0.028 -22.22% 720,000
24-04-23 0.036 0.00% 0
24-04-22 0.036 +5.88% 6,000
24-04-19 0.034 0.00% 0

Delayed Quote Hong Kong S.E., April 25, 2024 at 04:09 am EDT

More quotes

Company Profile

Kontafarma China Holdings Ltd, formely Tongfang Kontafarma Holdings Ltd, is an investment holding company principally engaged in pharmaceutical business. The Company operates its business through two business segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of prescription drugs, including chemical drugs and prescribed traditional Chinese medicines, and laboratory related products. The Fitness Business is segment is engaged in the operation of fitness centers, the provision of consultation services for fitness and health activities, as well as the operation of the franchise business for royalty fee income.
Sector
Pharmaceuticals
Calendar
2024-08-25 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
KONTAFARMA CHINA HOLDINGS LIMITED Stock Kontafarma China Holdings Limited
-11.11% 19.98M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.61% 660B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+24.05% 562B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.24% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.49% 322B
ABBVIE INC. Stock AbbVie Inc.
+8.28% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+12.74% 219B
ROCHE HOLDING AG Stock Roche Holding AG
-9.73% 196B
NOVARTIS AG Stock Novartis AG
+6.75% 199B
PFIZER, INC. Stock Pfizer, Inc.
-8.75% 149B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 1312 Stock